Legend Biotech Q4 Earnings Call Highlights [Yahoo! Finance]
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: Yahoo! Finance
reached profitability in 2025 with the company expecting enterprise-wide profitability in The therapy is now commercial in 14 global markets across treatment sites, and Legend has installed manufacturing capacity for 10,000 doses (planning up to with J&J) with overall manufacturing success rates around 97–99% Clinical data show strong durability and earlier use: median progression-free survival of 50.4 months in triple-class-exposed patients with three prior lines, and roughly of patients are being treated in the second-to-fourth-line setting. Interested in Legend Biotech Corporation Sponsored ADR? Here are five stocks we like better. CPI Data Sparks Rally in Biotech Stocks Legend Biotech (NASDAQ:LEGN) executives highlighted accelerating global demand for CARVYKTI, improving profitability metrics, and expanding manufacturing capacity during the company's fourth quarter 2025 earnings call. Management said CARVYKTI reached profitability in 2025 and the company expects to be pr
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Legend Biotech (LEGN) was upgraded by Truist Financial Corporation from "hold" to "strong-buy".MarketBeat
- Legend Biotech (LEGN) had its price target lowered by Morgan Stanley from $50.00 to $49.00. They now have an "overweight" rating on the stock.MarketBeat
- Legend Biotech (LEGN) had its price target lowered by Royal Bank Of Canada from $66.00 to $62.00. They now have an "outperform" rating on the stock.MarketBeat
- Legend Biotech (LEGN) was given a new $70.00 price target by Truist Financial Corporation.MarketBeat
- Legend Biotech Corp (LEGN) Q4 2025 Earnings Call Highlights: Record Growth and Profitability ... [Yahoo! Finance]Yahoo! Finance
LEGN
Sec Filings
- 3/10/26 - Form 20-F
- 3/10/26 - Form 6-K
- 2/6/26 - Form 6-K
- LEGN's page on the SEC website